alexa Novel Drug Therapies for the Treatment of Crohn's Disea
ISSN: 2161-069X

Journal of Gastrointestinal & Digestive System
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Novel Drug Therapies for the Treatment of Crohn's Disease

Pal Miheller1*, Agnes Anna Csontos1, Zsuzsanna Vegh1, András Gelley2 and Peter L. Lakatos1

12nd Department of Internal Medicine, Semmelweis University, H-1088 Budapest, Hungary

2Department of Internal Medicine and Gastroenterology, Polyclinic of the Hospitaller Brothers of St. John of God in Budapest, Hungary

*Corresponding Author:
Pal Miheller
2nd Department of Medicine
Semmelweis University, H-1088 Budapest
Szentkirályi u 46, Hungary
Tel: +36-63-4591500
Email: [email protected]

Received date: May 07, 2015; Accepted date: June 05, 2015; Published date: June 12, 2015

Citation: Miheller P, Csontos AA, Vegh Z, Gelley A, Lakatos PL (2015) Novel Drug Therapies for the Treatment of Crohn's Disease. J Gastrointest Dig Syst 5:297. doi: 10.4172/2161-069X.1000297

Copyright: © 2015 Miheller, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License; which permits unrestricted use; distribution; and reproduction in any medium; provided the original author and source are credited.

 

Abstract

Introduction: There was a recent revolution in the medical therapy of inflammatory bowel disease with the advent of anti-TNF inhibitors. Treatment paradigms have evolved from a slow step-up approach to accelerated care with early introduction of immunosuppression and biologicals. Areas covered: The authors review clinical efficacy and safety of new anti-TNFs and new action biologicals including anti-cytokine therapies and cell adhesion inhibitors in both Crohn’s disease. Some of the agents were already approved by both FDA and EMA. Expert opinion: Anti-TNF agents will remain the mainstay of biological therapy in in Crohn’s disease in the near future. However; the proportion of anti-TNF refractory patient population is growing. In addition; there is a change in the cost structure of inflammatory dowel disease and anti-TNFs became responsible for a great proportion of the direct costs; therefore new biolologicals including biosimilar anti-TNFS are urgently awaited. The addition of these drugy into the armamentarium will provide additional treatment option for both bionaive and refractory patients and hopefully it will lead to improved outcomes and on the long run to a lesser economic burden of the disease.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords